
Bristol-Myers Squibb Co
NYSE:BMY

Intrinsic Value
The intrinsic value of one
BMY
stock under the Base Case scenario is
88.84
USD.
Compared to the current market price of 74.67 USD,
Bristol-Myers Squibb Co
is
Undervalued by 16%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Bristol-Myers Squibb Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Bristol-Myers Squibb Co
BMY Capital Structure
Bristol-Myers Squibb Co
Market Capitalization | 159B USD | |
Total Debt | 37.2B USD | |
Minority Interest | 63M USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 7.7B USD | |
Short-Term Investments | 1.3B USD | |
Enterprise Value | 187B USD |
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for
BMY
is 83.2 USD
with a low forecast of 60.6 USD and a high forecast of 96.6 USD.
Competitive Landscape
BMY Competitors
Bristol-Myers Squibb Co
BMY Suppliers & Customers
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co has 93 key suppliers from 14 countries and 15 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Bristol-Myers Squibb Co has 64 key customers from 8 countries and 5 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Ownership
BMY Insider Trading
Buy and sell transactions by insiders
During the last 12 months Bristol-Myers Squibb Co insiders have not bought any shares, and sold 156M USD worth of shares. The last transaction was made on Feb 6, 2023 by Powell Ann (EVP, Chief Human Resources), who sold 3.9M USD worth of BMY shares.
Shareholder Return
BMY Price
Bristol-Myers Squibb Co
Average Annual Return | 4.21% |
Standard Deviation of Annual Returns | 15.87% |
Max Drawdown | -35% |
Market Capitalization | 159B USD |
Shares Outstanding | 2 135 260 032 |
Percentage of Shares Shorted | 1.15% |
Company Profile

Country
Industry
Market Cap
Dividend Yield
Description
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Contact
IPO
Employees
Officers
The intrinsic value of one
BMY
stock under the Base Case scenario is
88.84
USD.
Compared to the current market price of 74.67 USD, Bristol-Myers Squibb Co is Undervalued by 16%.